Physician profile
James S Zu
NPI 1083787824
$8,002.95
in general payments reported to CMS, 2019-2025
41 companies · $1,662 in 2025
The $1,662 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $767 · 2020: $603 · 2021: $802 · 2022: $1,064 · 2023: $1,525 · 2024: $1,580 · 2025: $1,662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,598 · Consulting Fee: $150 · Education: $18.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,597.66 |
| Consulting Fee | $150.00 |
| Education | $18.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,069.45 | 2019-2025 | |
| Abbvie INC. | $1,093.90 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Biogen, INC. | $1,053.44 | 2019-2025 | Tysabri, Vumerity, Avonex |
| Lilly USA, LLC | $554.13 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Ucb, INC. | $308.58 | 2019-2023 | Briviact, Nayzilam |
| Pfizer INC. | $277.91 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $267.99 | 2019-2025 | Austedo Xr, Austedo Xr |
| Argenx US, INC. | $216.49 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Csl Behring | $187.68 | 2020-2025 | Hizentra |
| Eisai INC. | $186.36 | 2020-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $172.87 | 2022 | |
| Amneal Pharmaceuticals LLC | $166.28 | 2019-2025 | Crexont, Ongentys 50mg Capsules 30 |
| Astrazeneca Pharmaceuticals LP | $148.53 | 2025 | Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2023 | Ofev |
| Alexion Pharmaceuticals, INC. | $121.49 | 2019-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Zu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.